Pliant Therapeutics, Inc. (PLRX) stock
PLRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.66−0.03 (-4.76%)
Close on Nov 17, 2026Market cap $40.88MP/E –Yield 0.00%
Pliant Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Pliant Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$70.90M. For fiscal 2025 it was -$128.34M. The highest annual figure on record is -$2.75M in fiscal 2019.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$128.34M | – |
| FY2024 | Dec 31, 2024 | -$155.50M | – |
| FY2023 | Dec 31, 2023 | -$116.36M | – |
| FY2022 | Dec 31, 2022 | -$94.63M | – |
| FY2021 | Dec 31, 2021 | -$75.44M | – |
| FY2020 | Dec 31, 2020 | -$37.27M | – |
| FY2019 | Dec 31, 2019 | -$2.75M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$12.80M | – |
| Q1 FY2026 | Mar 31, 2026 | -$19.23M | – |
| Q4 FY2025 | Dec 31, 2025 | -$17.79M | – |
| Q3 FY2025 | Sep 30, 2025 | -$21.08M | – |
| Q2 FY2025 | Jun 30, 2025 | -$40.60M | – |
| Q1 FY2025 | Mar 31, 2025 | -$48.86M | – |
| Q4 FY2024 | Dec 31, 2024 | -$47.66M | – |
| Q3 FY2024 | Sep 30, 2024 | -$32.27M | – |
| Q2 FY2024 | Jun 30, 2024 | -$45.30M | – |
| Q1 FY2024 | Mar 31, 2024 | -$30.27M | – |
| Q4 FY2023 | Dec 31, 2023 | -$25.10M | – |
| Q3 FY2023 | Sep 30, 2023 | -$36.22M | – |
| Q2 FY2023 | Jun 30, 2023 | -$24.76M | – |
| Q1 FY2023 | Mar 31, 2023 | -$30.28M | – |
| Q4 FY2022 | Dec 31, 2022 | -$31.24M | – |
| Q3 FY2022 | Sep 30, 2022 | -$18.50M | – |
| Q2 FY2022 | Jun 30, 2022 | -$24.40M | – |
| Q1 FY2022 | Mar 31, 2022 | -$20.50M | – |
| Q4 FY2021 | Dec 31, 2021 | -$19.87M | – |
| Q3 FY2021 | Sep 30, 2021 | -$22.51M | – |
| Q2 FY2021 | Jun 30, 2021 | -$19.40M | -349.7% |
| Q1 FY2021 | Mar 31, 2021 | -$13.67M | – |
| Q4 FY2020 | Dec 31, 2020 | -$16.49M | -144.9% |
| Q3 FY2020 | Sep 30, 2020 | -$15.79M | – |
| Q2 FY2020 | Jun 30, 2020 | $7.77M | – |
| Q1 FY2020 | Mar 31, 2020 | -$12.77M | – |
| Q4 FY2019 | Dec 31, 2019 | $36.74M | – |
| Q3 FY2019 | Sep 30, 2019 | -$14.88M | – |
See a number that looks wrong?